PURA - Puration Confirms Closing Acquisition To Bottle CBD Beverages In Europe
November 15 2019 - 11:16AM
InvestorsHub NewsWire
PURA – Puration Confirms Closing
Acquisition To Bottle CBD Beverages In Europe
Dallas, TX -- November 15, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today confirmed finalizing the acquisition of a German
company that will enable PURA to bottle its CBD beverages locally
for distribution throughout the European market. PURA
announced the closing of the acquisition yesterday. The
acquisition was driven by PURA recently signing a
distribution
agreement in
Europe for its EVERx CBD
Sports Water with other CBD infused beverages to
follow. The initial European distribution agreement is
estimated to add $4 million in sales next year. Management
indicates that the potential of European distribution beyond the
initial $4 million projection warrants the establishment of a local
bottling capacity. The European market for CBD is projected
to reach nearly US $17 billion
by 2023. The bottling expansion in Europe
is part of a bigger plan to expand bottling in Canada and Latin
America. PURA announced a letter of intent for a second
potential acquisition in Latin American similar to the acquisition
in Germany. It is designed to establish a foothold for local
bottling in the Latin American market just as the German
acquisition is designed to establish a foothold in Europe.
The legal Latin American cannabis market is anticipated to
reach $9 billion by
2028.
Look for more information soon on the Latin American
LOI.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains
forward-looking statements within the meaning of the Securities
Litigation Reform Act. The statements reflect the Company's current
views with respect to future events that involve risks and
uncertainties. Among others, these risks include the expectation
that any of the companies mentioned herein will achieve significant
sales, the failure to meet schedule or performance requirements of
the companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024